PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPossibly, but it is not a proven treatment. Researchers have tested a patient’s own bone marrow mononuclear cells (BMMNCs) in small studies of severe, acute traumatic brain injury (TBI). A randomized pediatric trial found the approach feasible and reported promising differences in intensive-care measures and brain imaging. It did not establish that the treatment improves long-term recovery for patients generally. In this context, BMMNC therapy remains investigational, not routine TBI care.
What is the bone-marrow treatment?
In the pediatric study, clinicians collected marrow from the patient, processed it under controlled conditions to isolate BMMNCs, and infused the cells into a vein within 48 hours of injury. This was an acute-care intervention delivered in a monitored clinical trial—not a treatment patients can obtain as an outpatient consumer procedure. The study describes this specific cell preparation and approach; its findings should not be generalized to every treatment marketed as stem-cell or bone-marrow therapy.
As an Amazon Associate I earn from qualifying purchases.
What did the pediatric clinical trial find?
The phase 2 study was randomized, double-masked, and placebo-sham-controlled at two U.S. children’s hospitals. It enrolled children and adolescents ages 5–17 with severe TBI, defined as a Glasgow Coma Scale score of 8 or less. Investigators randomized 47 participants; 37 completed one-year follow-up. Enrollment ended at 47 as funding wound down.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Investigators reported that treatment was safe and feasible in this trial. Compared with placebo, the BMMNC group had the following trial-specific differences:
#1 Best Overall
- Nearly 3 fewer ventilator days, reported as 23% fewer.
- 1 fewer day of intracranial-pressure monitoring, reported as 16% fewer.
- 3 fewer intensive-care-unit (ICU) days, reported as 14% fewer.
At one year, the treated group had less white-matter volume loss, with a statistically significant difference between groups. The corpus-callosum streamline comparison also favored the treated group, but variability was high and the result did not reach statistical significance (P = 0.055). These are findings from a small study, not population estimates or proof of better long-term function.
Does the evidence show that it improves recovery?
Not yet. ICU duration and imaging measures can help researchers evaluate a treatment, but an imaging difference does not by itself show that patients think, move, communicate, or live more independently as a result. The pediatric study’s size and follow-up also limit what can be concluded. Its results are a reason to study BMMNCs further, not a basis for treating the therapy as an established cure or routinely effective care.
An earlier adult phase I/IIa study enrolled participants from March 2012 to October 2014 at one center. It was open-label and nonrandomized, and reported early safety and feasibility findings along with a possible imaging tissue-preservation signal. Without randomization and a control group, that design cannot establish that the cells caused the observed findings or prove efficacy.
Who do these findings apply to?
The strongest evidence described here concerns children ages 5–17 with severe TBI who received treatment within 48 hours, in a clinical trial. It does not establish benefit for adults, mild TBI or concussion, chronic or remote brain injury, or other cell products, doses, processing methods, and routes of administration. A result from one acute-care protocol should not be treated as evidence for a different treatment or stage of injury.
Is bone-marrow cell treatment FDA-approved for TBI?
No TBI approval is established by these studies. The U.S. Food and Drug Administration says stem-cell products generally require FDA approval. The stem-cell products currently approved in the United States are cord-blood-derived hematopoietic progenitor cells for disorders affecting blood production; those approvals do not cover treatment of TBI. A study or registry listing is not FDA approval.
The FDA cautions: “The inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.” The agency also warns that unapproved regenerative medicine products can cause serious harms, including infections, tumors, and blindness. For its guidance, see the FDA’s information on unapproved stem cell and regenerative medicine products.
What should patients know about trial status?
The pediatric trial, NCT01851083, is completed; its actual primary completion was in September 2020. A source listing for adult trial NCT02525432 reports “Active, not recruiting,” but recruitment and site status should be confirmed directly. Registry entries can change, and a listing does not mean a trial is enrolling at a particular location or that its treatment is approved. Check the current pediatric trial registry entry and adult trial registry entry, then contact the study team to confirm status and eligibility.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsQuestions to ask a clinician or study team
- What exact cell product is being studied, and how is it collected and processed?
- Is this an FDA-overseen clinical trial, and what is the Investigational New Drug (IND) context?
- What are the eligibility criteria and treatment timing window?
- What risks, alternatives, and follow-up are involved?
- Is the trial recruiting at this site now, and who can confirm that directly?
Do not rely on promotional claims or a registry entry alone to determine whether a treatment is legally marketed, appropriate for a patient, or currently available.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
